
Biogen's Alzheimer's drug aducanumab implodes in a PhIII disaster — putting them at a perilous crossroads
Biogen’s big late-stage play in Alzheimer’s has just crashed. And the damage will be extensive.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.